Sk Biopharmaceuticals Co Ltd - Asset Resilience Ratio

Latest as of March 2026: 0.14%

Sk Biopharmaceuticals Co Ltd (326030) has an Asset Resilience Ratio of 0.14% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 326030 net working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

₩1.87 Billion

≈ $1.27 Million USD Cash + Short-term Investments

Total Assets

₩1.32 Trillion

≈ $894.83 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how Sk Biopharmaceuticals Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 326030 total assets.

Liquid Assets Composition Over Time

This chart breaks down Sk Biopharmaceuticals Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Sk Biopharmaceuticals Co Ltd (326030) financial obligations for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	₩0.00	0%
Short-term Investments	₩1.87 Billion	0.14%
Total Liquid Assets	₩1.87 Billion	0.14%

Asset Resilience Insights

Limited Liquidity: Sk Biopharmaceuticals Co Ltd maintains only 0.14% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Sk Biopharmaceuticals Co Ltd Industry Peers by Asset Resilience Ratio

Compare Sk Biopharmaceuticals Co Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
argenx NV ADR NASDAQ:ARGX	Biotechnology	15.95%
Madrigal Pharmaceuticals Inc NASDAQ:MDGL	Biotechnology	62.31%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	2.03%
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Tubize-Fin BR:TUB	Biotechnology	2.50%
Aurinia Pharmaceuticals Inc NASDAQ:AUPH	Biotechnology	33.23%
Nanobiotix NASDAQ:NBTX	Biotechnology	4.71%
Innovita Biological Technology Co. Ltd. A SHG:688253	Biotechnology	65.12%

Annual Asset Resilience Ratio for Sk Biopharmaceuticals Co Ltd (2016–2025)

The table below shows the annual Asset Resilience Ratio data for Sk Biopharmaceuticals Co Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	0.14%	₩1.71 Billion ≈ $1.16 Million	₩1.20 Trillion ≈ $812.08 Million	-0.02pp
2024-12-31	0.16%	₩1.68 Billion ≈ $1.14 Million	₩1.04 Trillion ≈ $702.63 Million	-0.03pp
2023-12-31	0.20%	₩1.42 Billion ≈ $961.23K	₩723.17 Billion ≈ $490.08 Million	-30.12pp
2022-12-31	30.32%	₩201.39 Billion ≈ $136.48 Million	₩664.24 Billion ≈ $450.15 Million	+13.48pp
2021-12-31	16.84%	₩108.42 Billion ≈ $73.47 Million	₩643.65 Billion ≈ $436.19 Million	-48.86pp
2020-12-31	65.70%	₩328.66 Billion ≈ $222.73 Million	₩500.24 Billion ≈ $339.01 Million	+43.24pp
2019-12-31	22.46%	₩31.23 Billion ≈ $21.17 Million	₩139.07 Billion ≈ $94.25 Million	+20.12pp
2018-12-31	2.34%	₩2.24 Billion ≈ $1.52 Million	₩95.54 Billion ≈ $64.74 Million	-37.39pp
2017-12-31	39.73%	₩39.08 Billion ≈ $26.48 Million	₩98.37 Billion ≈ $66.66 Million	-27.41pp
2016-12-31	67.14%	₩130.18 Billion ≈ $88.22 Million	₩193.89 Billion ≈ $131.40 Million	--

pp = percentage points

About Sk Biopharmaceuticals Co Ltd

KO:326030 Korea Biotechnology

Market Cap

$4.14 Billion

₩6.12 Trillion KRW

Market Cap Rank

#4016 Global

#90 in Korea

Share Price

₩78100.00

Change (1 day)

-1.26%

52-Week Range

₩74600.00 - ₩140700.00

All Time High

₩217000.00